佩索利单抗治疗泛发性脓疱型银屑病:31例病例汇总的真实世界数据分析OA

Objective To evaluate the efficacy and safety characteristics of spesolimab in real-world clinical practice among patients with generalized pustular psoriasis(GPP).Methods A combination of retrospective case series analysis and systematic literature review was employed.Clinical data of 5 GPP patients treated with spesolimab in our center were collected.All relevant published case reports from China were collected through a literature search.Observation indica-tors included time to complete pustule clearance,GPP Physician Global Assessment(GPPGA)score,GPP Area and Severity Index(GPPASI)score,and adverse events.Results A total of 31 patients were pooled for further analysis.The median time to complete pustule clearance was 2 days,with 45.16％(14/31)achieving clearance within 48 hours.All patients showed significant decreases in GPPGA and GPPASI scores on day 7 compared to the baseline.Five pregnant pa-tients and several elderly patients with severe comorbidities had good outcomes after treatment.In real-world practice,8 patients received an initial combination therapy of spesolimab and glucocor-ticoids.Regarding safety,the overall tolerability was good,but 32.26％(10/31)of patients ex-perienced exacerbation of pre-existing psoriatic erythema or developed new erythema.Conclusions In real-world clinical practice,spesolimab demonstrates rapid and potent efficacy in inducing remission in 31 Chinese GPP patients,including those who are pregnant or have complex comor-bidities.Combination with glucocorticoids is a common and effective strategy for managing severe cases.Close attention must be paid to its characteristic reaction of potentially exacerbating pre-ex-isting psoriatic lesions,and a comprehensive treatment plan encompassing both acute rescue and long-term management should be formulated.